EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland

Benzinga10-23

On Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477583804?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wtq7tzWxCCqVRuHExfrmRQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b45eadc510b3681db465693193010048","is_english":true,"pubTime":"2024-10-23 19:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2477583804","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland","media":"Benzinga","content":"<div>\n<p>On Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-virax-biolabs-inks-distribution-111546904.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-23 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exclusive-virax-biolabs-inks-distribution-111546904.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exclusive-virax-biolabs-inks-distribution-111546904.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4175","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://finance.yahoo.com/news/exclusive-virax-biolabs-inks-distribution-111546904.html","article_id":"2477583804","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wtq7tzWxCCqVRuHExfrmRQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b45eadc510b3681db465693193010048"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477583804","pubTimestamp":1729682146,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Wednesday, Virax Biolabs Group Limited  entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and Ireland through its wholly-owned subsidiary Cambridge Bioscience.\"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity...,\" said James Foster, CEO of Virax Biolabs.Also Read: Virax Biolabs Announces Stock Offering: What To Know.\"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies...\". \"We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland,\" commented Martijn Blommaart, Director of Supplier Development at Europa Biosite.In April this year, Virax Biolabs launched ‘ImmuneSelect’ within the ViraxImmune T-Cell diagnostic platform f","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4175":"保健护理产品经销商","VRAX":"Virax Biolabs Group Limited","BK4583":"猴痘概念"},"translate_title":"独家：Virax Biolabs签署分销协议，在英国和爱尔兰将ImmuneSelect分析解决方案商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRAX":0.9},"content_text":"On Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and Ireland through its wholly-owned subsidiary Cambridge Bioscience.\n\"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity...,\" said James Foster, CEO of Virax Biolabs.\nAlso Read: Virax Biolabs Announces Stock Offering: What To Know.\n\"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies...\"\n\"We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland,\" commented Martijn Blommaart, Director of Supplier Development at Europa Biosite.\nIn April this year, Virax Biolabs launched ‘ImmuneSelect’ within the ViraxImmune T-Cell diagnostic platform for research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress.\nImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID.\nProducts within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. \nThe ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens linked to post-viral syndromes. \nIn August, Virax Biolabs announced a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in some European and Gulf countries.\nThe RT PCR Mpox virus detection kits are approved for sale in Europe and also authorized by the Medicines and Healthcare Products Regulatory Agency, the product regulatory agency for the United Kingdom.\nPrice Action: VRAX stock closed at $1.68 on Tuesday.\nRead Next:\n\nPhilip Morris’ Raised Guidance Suggests Good Visibility: Goldman Sachs Analyst.\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477583804"}